ArticleSchizophrenia bulletin2026
Screening for Cognitive Decline in Psychotic Disorders in Midlife: Examining Scoring the Clinical Dementia Rating Using Longitudinal Data.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
background and hypothesisLittle is understood about whether the high reported prevalence of dementia in people with psychosis reflects impairment present at psychosis onset. We hypothesized that relying on longitudinal data would help to distinguish stable deficits associated with psychotic disorders from subsequent decline. STUDY
designWe prospectively assessed the Clinical Dementia Rating (CDR) in individuals with first-admission psychosis who have been followed for 25 years (109 with schizophrenia; 135 with other psychoses) alongside 238 demographically matched never-psychotic adults. We scored the CDR sum of boxes using data collected only once at the 25-year follow-up assessment and as a change from baseline, 25 years prior. Impairment was categorized as not observed (NI: CDR < 2.4), mild-moderate (MI: 2.4 ≤ CDR < 4.8), or severe (SI; CDR ≥ 4.8). Prevalence of MI/SI by clinical group was assessed. Multivariable-adjusted risk ratios (aRR) were estimated using multinomial logistic regression. STUDY
resultsMI/SI was common when assessed cross-sectionally, but prevalence decreased by 44.4-65.9% when longitudinal scoring was applied. Using longitudinal data, 11.6%/18.2% of participants with schizophrenia and 9.1%/3.8% of those with other psychosis had MI/SI respectively. Participants with schizophrenia were at an increased risk of MI (aRR = 4.98, 95% CI, 1.85-13.46, P = .002) and SI (aRR = 25.98 [3.50-192.75] P = .001) relative to never-psychotic adults. Secondarily, homozygotic apolipoprotein-ε4 carriers (2.6% of genotyped participants) with schizophrenia were at higher risk for SI at midlife (SRR = 2.57 [1.04-6.33] P = .04).
conclusionsFuture work should include observed decline in cognition and functioning to examine cognitive impairment in psychosis. Changes in CDR score may be important when managing treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.